SEC suspends China Medical trading amid accuracy concerns

The SEC has halted the trading of China Medical Technologies' ($CMEDY) American depository receipts for two weeks, pointing to concerns over the accuracy of the company's public disclosures, Bloomberg reports.

U.S. trading of the Chinese devicemaker's shares is suspended until July 13 as the SEC examines "questions that have been raised about the accuracy and adequacy of publicly disseminated information concerning, among other things," according to a statement from the SEC. That also includes "the status of the company's officers and directors [and] the accuracy of the company's financial statements and filings with the Commission." 

The suspension is yet another indignity in what seems like a death spiral for China Medical. Last month, as its depository receipts plummeted over two days, China Medical faced a petition from bondholders looking to liquidate the company entirely. Before that, in December, China Medical faced allegations that it was defrauding investors, with Glaucus Research Group claiming the company's balance sheet "presents numerous highly suspicious red flags."

The issue underscores a common concern for investors in Chinese firms: Their financial reporting and corporate governance are tough to trust, according to an analyst quoted by Bloomberg, and, as more and more Chinese companies have been delisted or suspended over the past two years, some Western investors are shying away.

- read the SEC statement
- get more from Bloomberg

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.